Reconstituted High-Density Lipoprotein Stimulates Differentiation of Endothelial Progenitor Cells and Enhances Ischemia-Induced Angiogenesis

Background—Plasma high-density lipoprotein (HDL) levels have an inverse correlation with incidence of ischemic heart disease as well as other atherosclerosis-related ischemic conditions. However, the molecular mechanism by which HDL prevents ischemic disease is not fully understood. Here, we investigated the effect of HDL on differentiation of endothelial progenitor cells and angiogenesis in murine ischemic hindlimb model. Methods and Results—Intravenous injection of reconstituted HDL (rHDL) significantly augmented blood flow recovery and increased capillary density in the ischemic leg. rHDL increased the number of bone marrow–derived cells incorporated into the newly formed capillaries in ischemic muscle. rHDL induced phosphorylation of Akt in human peripheral mononuclear cells. rHDL (50 to 100 &mgr;g apolipoprotein A-I/mL) promoted differentiation of peripheral mononuclear cells to endothelial progenitor cells in a dose-dependent manner. The effect of rHDL on endothelial progenitor cells differentiation was abrogated by coadministration of LY294002, an inhibitor of phosphatidylinositol 3-kinase. rHDL failed to promote angiogenesis in endothelial NO–deficient mice. Conclusions—rHDL directly stimulates endothelial progenitor cell differentiation via phosphatidylinositol 3-kinase/Akt pathway and enhances ischemia-induced angiogenesis. rHDL may be useful in the treatment of patients with ischemic cardiovascular diseases.

[1]  A M Zeiher,et al.  HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. , 2001, The Journal of clinical investigation.

[2]  H. Okano,et al.  Comparison of Various Bone Marrow Fractions in the Ability to Participate in Vascular Remodeling After Mechanical Injury , 2005, Stem cells.

[3]  J. Isner,et al.  Mouse model of angiogenesis. , 1998, The American journal of pathology.

[4]  Tomoko Nakanishi,et al.  ‘Green mice’ as a source of ubiquitous green cells , 1997, FEBS letters.

[5]  R. Nagai,et al.  Phosphatidylinositol 3-kinase: a key regulator of vascular tone? , 2002, Circulation research.

[6]  R. Nagai,et al.  Diverse Contribution of Bone Marrow Cells to Neointimal Hyperplasia After Mechanical Vascular Injuries , 2003, Circulation research.

[7]  A. Gotto,et al.  Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. , 2004, Journal of the American College of Cardiology.

[8]  G. Assmann,et al.  HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. , 2004, The Journal of clinical investigation.

[9]  H. Nishimatsu,et al.  Endothelial nitric oxide synthase is essential for the HMG‐CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  M. Makuuchi,et al.  Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis , 2002, Nature Medicine.

[11]  J. Isner,et al.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. , 1999, Circulation research.

[12]  S. Fichtlscherer,et al.  Number and Migratory Activity of Circulating Endothelial Progenitor Cells Inversely Correlate With Risk Factors for Coronary Artery Disease , 2001, Circulation research.

[13]  C. Heeschen,et al.  Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells , 2003, Nature Medicine.

[14]  I. Komuro,et al.  Critical Roles of Muscle-Secreted Angiogenic Factors in Therapeutic Neovascularization , 2006, Circulation research.

[15]  A. Quyyumi,et al.  Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. , 2003, The New England journal of medicine.

[16]  J. Isner,et al.  HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. , 2001, The Journal of clinical investigation.

[17]  T. Murohara,et al.  Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. , 2002, The Journal of clinical investigation.

[18]  Y. Seko,et al.  Genetic background influences therapeutic effectiveness of VEGF. , 2003, Biochemical and biophysical research communications.

[19]  T. Katagiri,et al.  Temporal and spatial characterization of cellular constituents during neointimal hyperplasia after vascular injury: Potential contribution of bone-marrow-derived progenitors to arterial remodeling. , 2004, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[20]  J. Wittes,et al.  Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.

[21]  J. Isner,et al.  Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Barter,et al.  High-Density Lipoproteins Enhance Progenitor-Mediated Endothelium Repair in Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[23]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[24]  P. Barter,et al.  Antiinflammatory Properties of HDL , 2004 .

[25]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[26]  M. Sata.  Role of Circulating Vascular Progenitors in Angiogenesis, Vascular Healing, and Pulmonary Hypertension: Lessons From Animal Models , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[27]  M. Moskowitz,et al.  Hypertension in mice lacking the gene for endothelial nitric oxide synthase , 1995, Nature.